Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection

Mechanisms of protective immunity to Staphylococcus aureus infection in humans remain elusive. While the importance of cellular immunity has been shown in mice, T cell responses in humans have not been characterised. Using a murine model of recurrent S. aureus peritonitis, we demonstrated that prior exposure to S. aureus enhanced IFNγ responses upon subsequent infection, while adoptive transfer of S. aureus antigen-specific Th1 cells was protective in naïve mice. Translating these findings, we found that S. aureus antigen-specific Th1 cells were also significantly expanded during human S. aureus bloodstream infection (BSI). These Th1 cells were CD45RO, indicative of a memory phenotype. Thus, exposure to S. aureus induces memory Th1 cells in mice and humans, identifying Th1 cells as potential S. aureus vaccine targets. Consequently, we developed a model vaccine comprising staphylococcal clumping factor A, which we demonstrate to be an effective human T cell antigen, combined with the Th1-driving adjuvant CpG. This novel Th1-inducing vaccine conferred significant protection during S. aureus infection in mice. This study notably advances our understanding of S. aureus cellular immunity, and demonstrates for the first time that a correlate of S. aureus protective immunity identified in mice may be relevant in

[1]  C. Weidenmaier,et al.  The Fall of a Dogma? Unexpected High T-Cell Memory Response to Staphylococcus aureus in Humans. , 2015, The Journal of infectious diseases.

[2]  T. Foster,et al.  Manipulation of Autophagy in Phagocytes Facilitates Staphylococcus aureus Bloodstream Infection , 2015, Infection and Immunity.

[3]  E. Wherry,et al.  Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection , 2015, Science.

[4]  S. Filler,et al.  OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , 111 ( 51 ) ISSN 0027-8424 , 2014 .

[5]  Najaf A. Shah,et al.  Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: An analysis of possible contributing host factors , 2014, Human vaccines & immunotherapeutics.

[6]  P. Schlievert,et al.  Models matter: the search for an effective Staphylococcus aureus vaccine , 2014, Nature Reviews Microbiology.

[7]  V. Fowler,et al.  Where does a Staphylococcus aureus vaccine stand? , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  T. Foster,et al.  Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus. , 2014, The Journal of infectious diseases.

[9]  K. Mills,et al.  Staphylococcus aureus Infection of Mice Expands a Population of Memory γδ T Cells That Are Protective against Subsequent Infection , 2014, The Journal of Immunology.

[10]  T. Foster,et al.  A short sequence within subdomain N1 of region A of the Staphylococcus aureus MSCRAMM clumping factor A is required for export and surface display. , 2014, Microbiology.

[11]  A. Chong,et al.  Protective Immunity against Recurrent Staphylococcus aureus Skin Infection Requires Antibody and Interleukin-17A , 2014, Infection and Immunity.

[12]  Jesse B. Hall,et al.  Immune Dysfunction Prior to Staphylococcus aureus Bacteremia Is a Determinant of Long-Term Mortality , 2014, PloS one.

[13]  B. Segal,et al.  In vitro polarization of T-helper cells. , 2014, Methods in molecular biology.

[14]  G. Corey,et al.  Methicillin-resistant Staphylococcus aureus: an evolving pathogen. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  E. Lavelle,et al.  Nlrp-3-Driven Interleukin 17 Production by γδT Cells Controls Infection Outcomes during Staphylococcus aureus Surgical Site Infection , 2013, Infection and Immunity.

[16]  H. Schønheyder,et al.  A nationwide study of comorbidity and risk of reinfection after Staphylococcus aureus bacteraemia. , 2013, The Journal of infection.

[17]  C. Welch,et al.  Thirty-day mortality in UK patients with community-onset and hospital-acquired meticillin-susceptible Staphylococcus aureus bacteraemia. , 2013, The Journal of hospital infection.

[18]  R. Betts,et al.  Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. , 2013, JAMA.

[19]  K. Mills,et al.  Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.

[20]  A. van Belkum,et al.  Characterization of the Humoral Immune Response during Staphylococcus aureus Bacteremia and Global Gene Expression by Staphylococcus aureus in Human Blood , 2013, PloS one.

[21]  C. Tapia P [NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults]. , 2013, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.

[22]  S. Filler,et al.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. , 2012, Vaccine.

[23]  S. Cosgrove,et al.  Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. , 2012, The Journal of infectious diseases.

[24]  Manmohan J. Singh,et al.  The vaccine adjuvant alum inhibits IL‐12 by promoting PI3 kinase signaling while chitosan does not inhibit IL‐12 and enhances Th1 and Th17 responses , 2012, European journal of immunology.

[25]  M. Aman,et al.  Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. , 2012, The Journal of infectious diseases.

[26]  D. Cooper,et al.  Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors , 2012, Human vaccines & immunotherapeutics.

[27]  H. Aamot,et al.  Genotyping of 353 Staphylococcus aureus Bloodstream Isolates Collected between 2004 and 2009 at a Norwegian University Hospital and Potential Associations with Clinical Parameters , 2012, Journal of Clinical Microbiology.

[28]  Y. Zhuang,et al.  Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia , 2012, BMC Immunology.

[29]  S. V. van Hal,et al.  Predictors of Mortality in Staphylococcus aureus Bacteremia , 2012, Clinical Microbiology Reviews.

[30]  R. Proctor,et al.  Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model , 2012, Human vaccines & immunotherapeutics.

[31]  W. Brown,et al.  CD4 T Cell Antigens from Staphylococcus aureus Newman Strain Identified following Immunization with Heat-Killed Bacteria , 2012, Clinical and Vaccine Immunology.

[32]  B. Spellberg,et al.  Development of a vaccine against Staphylococcus aureus , 2011, Seminars in Immunopathology.

[33]  R. Gavrieli,et al.  Lessons Learned from Phagocytic Function Studies in a Large Cohort of Patients with Recurrent Infections , 2011, Journal of Clinical Immunology.

[34]  S. Engelmann,et al.  Distinctive patterns in the human antibody response to Staphylococcus aureus bacteremia in carriers and non‐carriers , 2011, Proteomics.

[35]  N. Rooijen,et al.  SHIP‐deficient, alternatively activated macrophages protect mice during DSS‐induced colitis , 2011, Journal of leukocyte biology.

[36]  Manuel T. Silva Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation , 2011, Journal of leukocyte biology.

[37]  V. Gant,et al.  Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? , 2011, Nature Reviews Microbiology.

[38]  R. Landmann,et al.  T and B Cells Are Not Required for Clearing Staphylococcus aureus in Systemic Infection Despite a Strong TLR2–MyD88-Dependent T Cell Activation , 2011, The Journal of Immunology.

[39]  L. Bopp,et al.  IFN-gamma enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics. , 2010, Cytokine.

[40]  Y. Iwakura,et al.  Role of Interleukin-17A in Cell-Mediated Protection against Staphylococcus aureus Infection in Mice Immunized with the Fibrinogen-Binding Domain of Clumping Factor A , 2010, Infection and Immunity.

[41]  J. Lindsay,et al.  Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions , 2010, BMC Microbiology.

[42]  E. Pietras,et al.  IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. , 2010, The Journal of clinical investigation.

[43]  A. van Belkum,et al.  Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[44]  T. Foster,et al.  Molecular Characterization of the Interaction of Staphylococcal Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM) ClfA and Fbl with Fibrinogen* , 2009, The Journal of Biological Chemistry.

[45]  J. Farber,et al.  Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice , 2009, PLoS pathogens.

[46]  H. Takada,et al.  Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome , 2009, The Journal of experimental medicine.

[47]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[48]  Dirk Roos,et al.  Chronic Granulomatous Disease: The European Experience , 2009, PloS one.

[49]  C. Sasakawa,et al.  Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. , 2009, Immunity.

[50]  K. Laupland,et al.  Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. , 2008, The Journal of infectious diseases.

[51]  N. Litjens,et al.  Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. , 2008, Journal of the American Society of Nephrology : JASN.

[52]  P. Lipke,et al.  The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus , 2008, Infection and Immunity.

[53]  W. Paul,et al.  Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome , 2008, Nature.

[54]  D. Robinson,et al.  Fnbpb Fibronectin-binding Proteins, Fnbpa and Phenotype Mediated by the Biofilm Staphylococcus Aureus a Novel , 2008 .

[55]  Timothy Foster,et al.  A Potential New Pathway for Staphylococcus aureus Dissemination: The Silent Survival of S. aureus Phagocytosed by Human Monocyte-Derived Macrophages , 2008, PloS one.

[56]  D. Kasper,et al.  IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection. , 2008, Journal of immunology.

[57]  F. Venet,et al.  Monitoring Immune Dysfunctions in the Septic Patient: A New Skin for the Old Ceremony , 2008, Molecular medicine.

[58]  Bodo Grimbacher,et al.  STAT3 mutations in the hyper-IgE syndrome. , 2007, The New England journal of medicine.

[59]  W. Greiner,et al.  Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[60]  C. Parish,et al.  Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester , 2007, Nature Protocols.

[61]  O. Schneewind,et al.  Vaccine assembly from surface proteins of Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences.

[62]  A. Tzianabos,et al.  CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections , 2006, Proceedings of the National Academy of Sciences.

[63]  T. Foster Immune evasion by staphylococci , 2005, Nature Reviews Microbiology.

[64]  A. Watts,et al.  Staphylococcus aureus Strains That Express Serotype 5 or Serotype 8 Capsular Polysaccharides Differ in Virulence , 2005, Infection and Immunity.

[65]  B. Kocsis,et al.  Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients , 2005, Clinical Diagnostic Laboratory Immunology.

[66]  M. Chatterji,et al.  INFECTION-INDUCED MODULATION OF M1 AND M2 PHENOTYPES IN CIRCULATING MONOCYTES: ROLE IN IMMUNE MONITORING AND EARLY PROGNOSIS OF SEPSIS , 2004, Shock.

[67]  H. Wertheim,et al.  Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers , 2004, The Lancet.

[68]  N. Van Rooijen,et al.  Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.

[69]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[70]  S. Holland,et al.  Long-term interferon-gamma therapy for patients with chronic granulomatous disease. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  D. Christmann,et al.  Role of Comorbidity in Mortality Related to Staphylococcus aureus Bacteremia: A Prospective Study Using the Charlson Weighted Index of Comorbidity , 2003, Infection Control & Hospital Epidemiology.

[72]  P. van Endert,et al.  A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. , 2003, Journal of immunological methods.

[73]  H. Davies,et al.  Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. , 2003, The Journal of infectious diseases.

[74]  S. Foster,et al.  σB Modulates Virulence Determinant Expression and Stress Resistance: Characterization of a Functional rsbU Strain Derived from Staphylococcus aureus 8325-4 , 2002, Journal of bacteriology.

[75]  M. de Maeyer,et al.  Staphylokinase-Specific Cell-Mediated Immunity in Humans1 , 2002, The Journal of Immunology.

[76]  T. Foster,et al.  Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. , 2001, The Journal of infectious diseases.

[77]  J. Shellito,et al.  Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense , 2001, The Journal of experimental medicine.

[78]  Julia Y. Wang,et al.  Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  B. Spellberg,et al.  Type 1/Type 2 immunity in infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  K. Heeg,et al.  CpG‐oligodeoxynucleotides enhance T‐cell receptor‐triggered interferon‐γ production and up‐regulation of CD69 via induction of antigen‐presenting cell‐derived interferon type I and interleukin‐12 , 2000, Immunology.

[81]  M. Helbert,et al.  A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test. , 1998, Journal of immunological methods.

[82]  Zhao,et al.  The dual role of interferon‐γ in experimental Staphylococcus aureus septicaemia versus arthritis , 1998, Immunology.

[83]  A. Tarkowski,et al.  Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. , 1995, Journal of immunology.

[84]  F. Chang,et al.  Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus. , 1995, Diabetes research and clinical practice.

[85]  R. Coffman,et al.  IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. , 1988, Journal of immunology.